UBS analyst Ashwani Verma lowered the price target on Biogen (NASDAQ: BIIB) to $134.00 (from $157.00) while maintaining a Neutral ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE